

Supplemental Material to:

**Paula L Hyland, Laura S Burke, Ruth M Pfeiffer,
Melissa Rotunno, David Sun, Prasad Patil, Xiaolin Wu,
Margaret A Tucker, Alisa M Goldstein,
and Xiaohong Rose Yang**

**Constitutional promoter methylation and risk of familial
melanoma**

Epigenetics 2013; 9(5)

<http://dx.doi.org/10.4161/epi.28151>

**[https://www.landesbioscience.com/journals/epigenetics/
article/28151/](https://www.landesbioscience.com/journals/epigenetics/article/28151/)**

Table S1. *P*-values for association between overall methylation of each gene-specific promoter and demographic or cutaneous malignant melanoma (CMM) risk factors among non-carrier controls.

| Risk Factor | <i>CDH1</i> | <i>COL1A2</i> | <i>DAPK1</i> | <i>DDIT4L</i> | <i>HSPB6</i> | <i>LOX</i> | <i>MAGE-A3 (females)</i> | <i>MAGE-A3 (males)</i> | <i>MT1G</i> | <i>NPM2</i> | <i>p14ARF</i> | <i>p16</i> | <i>PTEN</i> | <i>RASSF1</i> | <i>TNFRSF10C</i> | <i>TNFRSF10D</i> |
|-------------------|--------------|---------------|--------------|---------------|--------------|--------------|--------------------------|------------------------|--------------|--------------|------------------|--------------|--------------|---------------|------------------|------------------|
| Age at blood draw | 0.179 | 0.070 | 0.748 | 0.001 | 0.932 | 0.506 | 0.984 | 0.878 | 0.881 | 0.312 | 0.003 | 0.122 | 0.656 | 0.529 | 0.494 | 0.261 |
| Gender | 0.806 | 0.038 | 0.858 | 0.198 | 0.134 | 0.280 | -- | -- | 0.100 | 0.078 | 0.748 | 0.027 | 0.701 | 0.674 | 0.060 | 0.557 |
| Dysplastic nevi | 0.875 | 0.042 | 0.940 | 0.847 | 0.967 | 0.035 | 0.311 | <.0001 | 0.405 | 0.697 | <.0001 | 0.579 | 0.375 | 0.462 | 0.889 | 0.237 |
| Moles | 0.048 | 0.012 | 0.847 | 0.425 | 0.414 | 0.608 | 0.524 | 0.004 | 0.225 | 0.679 | 0.280 | 0.032 | 0.174 | 0.787 | 0.250 | 0.013 |
| Freckles | 0.199 | 0.560 | 0.193 | 0.097 | 0.304 | 0.324 | 0.497 | 0.049 | 0.112 | 0.556 | 0.575 | 0.653 | 0.789 | 0.847 | 0.774 | 0.706 |
| Solar injury | 0.962 | 0.523 | 0.183 | 0.619 | 0.741 | 0.626 | 0.376 | <.0001 | 0.625 | 0.927 | 0.995 | 0.404 | 0.767 | 0.889 | 0.680 | 0.839 |
| Tanning ability | 0.744 | 0.513 | 0.784 | 0.157 | 0.975 | 0.672 | 0.080 | <.0001 | 0.932 | 0.516 | 0.870 | 0.374 | 0.422 | 0.353 | 0.364 | 0.374 |
| Skin type | 0.315 | 0.628 | 0.633 | 0.700 | 0.648 | 0.785 | 0.511 | 0.0001 | 0.578 | 0.315 | 0.923 | 0.836 | 0.035 | 0.449 | 0.218 | 0.588 |
| Eye color | 0.009 | 0.678 | 0.007 | 0.0004 | 0.012 | 0.005 | 0.252 | 0.069 | 0.183 | 0.003 | 0.466 | 0.371 | 0.019 | 0.172 | 0.084 | 0.308 |
| Hair color | 0.004 | 0.480 | 0.014 | 0.477 | 0.013 | 0.104 | 0.014 | <.0001 | 0.011 | 0.005 | 0.763 | 0.291 | 0.245 | 0.251 | 0.066 | 0.106 |
| <i>MC1R</i> | 0.019 | 0.593 | 0.144 | 0.016 | 0.358 | 0.459 | 0.685 | <.0001 | 0.660 | 0.924 | 0.234 | 0.041 | 0.028 | 0.004 | 0.880 | 0.245 |

P-values were obtained using a generalized estimating equation and adjusting for familial correlation. The significance of each risk factor in non-carrier controls (n= 90) was assessed with all of the other risk factors included in the model. *P*-values <0.05 are bolded. Normality testing of residuals was met for each gene target with the exception of *RASSF1*, *DAPK1* and *CDH1*. For *CDH1* and *DAPK1*, data normality was achieved using log transformation. For *RASSF1*, normality of residuals was not achieved.

Table S2. Association between gene-specific promoter methylation and CMM status.

| Promoter | Model 1 | | | | Model 2 | | | |
|--------------------------|---------|--------|------|------------------|---------|--------|------|--------------|
| | OR | 95% CI | | P | OR | 95% CI | | P |
| <i>CDH1</i> | 0.78 | 0.66 | 0.91 | 0.002 | 0.84 | 0.71 | 1.00 | 0.052 |
| <i>COL1A2</i> | 1.00 | 0.98 | 1.02 | 0.906 | 1.00 | 0.97 | 1.03 | 0.991 |
| <i>DAPK1</i> | 0.76 | 0.63 | 0.93 | 0.007 | 0.78 | 0.61 | 1.01 | 0.056 |
| <i>DDIT4L</i> | 0.77 | 0.54 | 1.11 | 0.166 | 0.72 | 0.49 | 1.08 | 0.115 |
| <i>HSPB6</i> | 0.98 | 0.95 | 1.01 | 0.188 | 0.98 | 0.93 | 1.02 | 0.286 |
| <i>LOX</i> | 0.84 | 0.68 | 1.03 | 0.096 | 1.01 | 0.78 | 1.30 | 0.952 |
| <i>MAGE-A3 (females)</i> | 0.64 | 0.50 | 0.82 | 0.001 | 0.75 | 0.63 | 0.89 | 0.002 |
| <i>MAGE-A3 (males)</i> | 0.81 | 0.66 | 1.01 | 0.060 | | | | |
| <i>MT1G</i> | 0.86 | 0.79 | 0.94 | 0.001 | 0.88 | 0.80 | 0.97 | 0.011 |
| <i>NPM2</i> | 0.79 | 0.51 | 1.21 | 0.275 | 0.82 | 0.53 | 1.27 | 0.372 |
| <i>p14ARF</i> | 0.30 | 0.12 | 0.74 | 0.009 | 0.28 | 0.10 | 0.77 | 0.013 |
| <i>p16</i> | 0.75 | 0.42 | 1.32 | 0.319 | 0.64 | 0.35 | 1.18 | 0.155 |
| <i>PTEN</i> | 0.52 | 0.29 | 0.95 | 0.034 | 0.51 | 0.26 | 0.98 | 0.044 |
| <i>RASSF1</i> | 0.29 | 0.11 | 0.81 | 0.018 | 0.30 | 0.10 | 0.86 | 0.026 |
| <i>TNFRSF10C</i> | 0.63 | 0.50 | 0.80 | <0.001 | 0.64 | 0.47 | 0.87 | 0.004 |
| <i>TNFRSF10D</i> | 0.61 | 0.43 | 0.87 | 0.006 | 0.57 | 0.39 | 0.84 | 0.004 |

Model 1: Adjusted for age, sex and *CDKN2A* mutation status.

Model 2: Adjusted for age, sex, *CDKN2A* mutation status, moles and hair color.

P-values (*P*) were obtained by comparing CMM cases to unaffected individuals using a generalized estimating equation and adjusting for familial correlation. *P*-value surviving Bonferroni correction for multiple comparisons (0.05/15, *P*= 0.003) are bolded.